Corticosteroid in non-COVID-19 induced community-acquired pneumonia, a meta-analysis
Copyright © 2024. Published by Elsevier Inc..
BACKGROUND: Corticosteroid treatment in non-COVID-19 induced Community-acquired pneumonia (CAP) remains inconclusive.
OBJECTIVES: We aimed to assess the role of corticosteroid treatment in CAP.
METHODS: We conducted a comprehensive search of online databases, including PubMed, Embase, and Cochrane, to identify articles published from January 1, 2000, to May 5, 2023. Double-blind RCTs were selected. Two authors screened studies and extracted data. The evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach.
RESULTS: We analyzed data from 12 RCTs, involving 2446 patients. Corticosteroids therapy may reduce short-term mortality in patients with severe CAP (sCAP) and shorten the hospital length of stay in patients with CAP. Furthermore, corticosteroids treatment can decrease the risk of requiring mechanical ventilation, developing septic shock and multiple organ dysfunction syndrome (MODS). There were no significant differences between the corticosteroid and control groups concerning gastrointestinal bleeding and nosocomial infection. The use of corticosteroids could increase the risk of hyperglycemia.
CONCLUSION: Corticosteroid treatment for sCAP has the potential to provide benefits in reducing short-term mortality, but this conclusion necessitates more evidence. Besides, we found no evidence that strongly prevents us from using corticosteroids in patients with sCAP or those at risk of progressing to sCAP.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Heart & lung : the journal of critical care - 65(2024) vom: 28. Apr., Seite 59-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Jian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 09.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.hrtlng.2024.02.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369219104 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369219104 | ||
| 003 | DE-627 | ||
| 005 | 20240409232531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.hrtlng.2024.02.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM369219104 | ||
| 035 | |a (NLM)38432039 | ||
| 035 | |a (PII)S0147-9563(24)00026-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Jian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Corticosteroid in non-COVID-19 induced community-acquired pneumonia, a meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a BACKGROUND: Corticosteroid treatment in non-COVID-19 induced Community-acquired pneumonia (CAP) remains inconclusive | ||
| 520 | |a OBJECTIVES: We aimed to assess the role of corticosteroid treatment in CAP | ||
| 520 | |a METHODS: We conducted a comprehensive search of online databases, including PubMed, Embase, and Cochrane, to identify articles published from January 1, 2000, to May 5, 2023. Double-blind RCTs were selected. Two authors screened studies and extracted data. The evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation approach | ||
| 520 | |a RESULTS: We analyzed data from 12 RCTs, involving 2446 patients. Corticosteroids therapy may reduce short-term mortality in patients with severe CAP (sCAP) and shorten the hospital length of stay in patients with CAP. Furthermore, corticosteroids treatment can decrease the risk of requiring mechanical ventilation, developing septic shock and multiple organ dysfunction syndrome (MODS). There were no significant differences between the corticosteroid and control groups concerning gastrointestinal bleeding and nosocomial infection. The use of corticosteroids could increase the risk of hyperglycemia | ||
| 520 | |a CONCLUSION: Corticosteroid treatment for sCAP has the potential to provide benefits in reducing short-term mortality, but this conclusion necessitates more evidence. Besides, we found no evidence that strongly prevents us from using corticosteroids in patients with sCAP or those at risk of progressing to sCAP | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Community-acquired pneumonia | |
| 650 | 4 | |a Corticosteroid | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Hydrocortisone | |
| 650 | 4 | |a Methylprednisolone | |
| 650 | 4 | |a Severe community-acquired pneumonia | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Dong, Yongquan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jia |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Yuqing |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Yunqing |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Lingtong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heart & lung : the journal of critical care |d 1973 |g 65(2024) vom: 28. Apr., Seite 59-71 |w (DE-627)NLM00000460X |x 1527-3288 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g day:28 |g month:04 |g pages:59-71 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.hrtlng.2024.02.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |b 28 |c 04 |h 59-71 | ||